ADAMTS7 and atrial fibrillation: In our study, the ADAMTS7 promoter was partially methylated with a mean methylation percentage estimated at 16% in AF patients and controls, and an approximate difference of 4% (t0-t2) was statistically significant in bleeding AF patients.